Simultaneous screening for head and neck, lung cancers may improve early detection, survival
the ONA take:
According to a new analysis published in the journal Cancer, researchers from the University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania, have found that screening patients for head and neck cancer and lung cancer could improve early detection and survival.
The multidisciplinary team analyzed data from 3,587 patients from the Pittsburgh Lung Screening Study (PLuSS) to investigate whether those patients, which included both current and ex-smokers, had a higher risk of developing head and neck cancer.
Results showed that the rate of head and neck cancer among the PLuSS participants was 71.4 cases annually per 100,000 people compared with the expected 43 cases annually per 100,000 in the general U.S. population.
Because head and neck cancer is rare in comparison to the most common cancer types, the researchers note that it would be impractical to screen the general population for the disease, but patients at risk for lung cancer that would be referred for lung cancer screening would most likely benefit from head and neck cancer screenings as well.
The researchers are now designing a national study to assess the effect of simultaneous lung and head and neck cancer screening on mortality.
Screening patients for head and neck cancer and lung cancer could improve early detection and survival.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|